{
  "docId": "019de072-ece7-71de-8eba-0df52639d987",
  "docSlug": "f4caf3b83872d8591c78c133c07757ed",
  "documentTitle": "BenevolentAI | Investor Presentation Deck | 19 slides",
  "authorId": "benevolentai",
  "authorName": "BenevolentAI",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-06-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 10,
  "pageCount": 19,
  "prevPage": 9,
  "nextPage": 11,
  "slideType": "problem_statement",
  "function": "frame_problem",
  "density": "dense",
  "nDataPoints": 3,
  "notes": "The slide uses a split-layout: left side defines the disease burden and market, right side defines the drug mechanism.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de072-ece7-71de-8eba-0df52639d987/10",
  "deckHref": "/decks/019de072-ece7-71de-8eba-0df52639d987",
  "deckJsonHref": "/decks/019de072-ece7-71de-8eba-0df52639d987.json",
  "deckAnchorHref": "/decks/019de072-ece7-71de-8eba-0df52639d987#slide-10",
  "components": [
    {
      "bbox": {
        "h": 0.08,
        "w": 0.45,
        "x": 0.5,
        "y": 0.15
      },
      "kind": "callout",
      "text": "BEN-2293: A potent PanTrk antagonist developed to relieve inflammation and provide rapid itch resolution in patients with AD",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d63119b1-8f88-419c-b4b1-52228a8eb979",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.6,
        "w": 0.42,
        "x": 0.05,
        "y": 0.18
      },
      "kind": "list",
      "text": "Atopic dermatitis is the most common chronic inflammatory skin disease... Affects 10-20% of children... 60-70% of all cases... market value in 7MM forecast to exceed $14 billion...",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "50c539a7-4e06-471a-8b67-4dd9baa3e6f3",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.6,
        "w": 0.42,
        "x": 0.52,
        "y": 0.28
      },
      "kind": "paragraph",
      "text": "BEN-2293 is a PanTrk inhibitor targeting TrkA,B and C receptors... BEN-2293 is expected to treat atopic dermatitis by... BEN-2293 will target Mild, Moderate and Severe Atopic Dermatitis patients...",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "11570cd7-8e12-4b48-a9d8-2a61b558fd33",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.4,
        "x": 0.02,
        "y": 0.93
      },
      "kind": "source-note",
      "text": "Source: (1) GlobalData — Atopic Dermatitis: Global Drug Forecast and Market Analysis to 2027; Evaluate Pharma - Eczema/Dermatitis: Worldwide Sales 2026 (2) GlobalData — Atopic Dermatitis: Epidemiology Forecast to 2027",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e84c8c8a-03ba-4aa5-9c5b-cfc765409207",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.4,
        "x": 0.05,
        "y": 0.06
      },
      "kind": "title",
      "text": "BEN-2293 -Atopic Dermatitis (AD)",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c797b55c-7ed8-4970-99bf-95ce72be7145",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Problem Statement Canvas",
      "slug": "problem-statement-canvas",
      "agent": "Architect",
      "layer": "slide",
      "matchId": "a96b9071-d94a-49df-b817-c7509a03c9aa",
      "evidence": "Atopic dermatitis is the most common chronic inflammatory skin disease...",
      "confidence": 0.7
    }
  ],
  "frameworks": [],
  "arcBeats": [],
  "loops": [
    {
      "to": 11,
      "from": 3,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "8b4989da-37eb-42d1-a462-8ea57fa882d7",
      "evidence": "Drug development is failing patients and BenevolentAI's solution",
      "position": 0,
      "objective": "Highlight the cost of inaction in drug development",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.7,
      "description": "Quantify what happens if the audience does nothing"
    },
    {
      "to": 15,
      "from": 10,
      "name": "Quick Win Big Bet",
      "slug": "47-quick-win-big-bet",
      "bestFor": "Transformation planning, 100-day plans, resource allocation",
      "matchId": "b60aafe0-945b-4485-b373-af4183f36f2b",
      "evidence": "BEN-2293 and BEN-8744 progress",
      "position": 1,
      "objective": "Showcase quick wins and big bets in pipeline",
      "structure": "The Full List -> Quick Wins (Low effort, High impact) -> Big Bets (High effort, High impact) -> Sequenced Roadmap",
      "confidence": 0.6,
      "description": "Separate initiatives into immediate wins and longer-term strategic bets"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}